AbClon KRX:174900KOSDAQ

앱클론 · Korean news coverage and regulatory filings, organized.

Articles, 24h0
Articles, 7 days23
DART filings, 7 days1
Articles tracked76since Sep 11

In Q3 2026, AbClon reported revenue of ₩1.8bn, up 12.9% year on year, and an operating loss of ₩3.9bn. AbClon (앱클론) appeared in 23 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Nov 9 with 17 articles. The most common catalyst was tech & capacity (15). It was most often mentioned alongside Chong Kun Dang Pharmaceutical, 글로벌테크놀로지 and Kangstem Biotech.

Filing signals Supply contract Clinical trial filing 4 quarters of losses Screener

AbClon today: up or down?

No sign-up, one tap a day. These numbers show what visitors think and are not investment advice.

Upcoming dates as filed

  • Mar 31 Annual report filing deadlinein 134 days · period ending Dec 2026

Dates AbClon stated in its DART filings. A conversion period opening does not mean new shares appear that day; bondholders must request conversion.

AbClon quarterly results separate, KRW

QuarterRevenueYoYOperating profitNet income
Q3 2026₩1.8bn+12.9%−₩3.9bn
margin −219.8%
−₩3.8bn
Q2 2026₩1.7bn+51.4%−₩6.3bn−₩6.1bn
Q1 2026₩434m+5.2%−₩3.1bn−₩2.8bn
Q4 2025 derived₩1.6bn+128.6%−₩5.0bn−₩5.1bn
Q3 2025₩1.6bn+96.3%−₩3.5bn
margin −225.9%
−₩3.5bn
Q2 2025₩1.1bn+181.8%−₩3.3bn−₩3.5bn
Q1 2025₩413m-5.6%−₩5.8bn−₩6.0bn
Q4 2024 derived₩710m+26.0%−₩3.2bn−₩3.3bn

AbClon ranks #2156 of 2,345 Korean listed companies by Q3 2026 operating profit. Q3 2026 Korean earnings rankings →

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

AbClon top stories 2 weeks, by number of outlets

  1. 1
    Appclone, Chong Kun Dang sign exclusive domestic sales contract for CAR-T therapy Nesphacel
    13 outlets · 13 articlesFirst report Nov 9 13:01 메디컬투데이Order / supply contractChong Kun Dang Pharmaceutical
  2. 2
  3. 3
    AppClone's CAR-T 'Nespercell' receives European patent…secures rights in eight major markets
    6 outlets · 6 articlesFirst report Nov 11 09:05 더바이오New technology
  4. 4
  5. 5
    AppClone's HLX22 opens possibility of big pharma retransfer… Hengruis' choice
    1 outlets · 1 articlesFirst report Nov 13 07:25 메디코파마Licensing deal
  6. 6

Latest AbClon news Korean headlines